Cubist Pharma Buying Calixa for Up To $402 Million
Cubist Pharmaceuticals Inc. (Nasdaq: CBST) has agreed to acquire Calixa Therapeutics Inc., a San Diego-based developer of drugs that address multi-drug resistant Gram-negative pathogens. The deal includes a $92.5 up-front cash payment, plus up to $310 million in earnout payments. Calixa raised around $28 million in VC funding, from Canaan Partners, Domain Associates and Frazier Healthcare Ventures.
14 December 2009•4 mins read
